Program
MMH-407
A development code. Also written as “Raphamin”.
Its studies are mostly in Bronchitis · Rhinosinusitis · Cystitis · Community-Acquired Pneumonia · COVID-19, led by Materia Medica.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Materia Medica | 94 open or running | phase 3since Dec 13, 2019 | Dec 13, 2019 | Dec 31, 2026phase 3 · NCT06284265 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 13, 2019First study: phase 3 study in Viral Respiratory InfectionFirst studyNCT04244084 · 240 enrolled · Russian Federation
- Jan 29, 2020Phase 3 study in Influenza, HumanNCT04250311 · 314 enrolled · Russian Federation
- May 21, 2021Phase 3 study in Acute Respiratory Viral InfectionNCT04918771 · 435 enrolled · Russian Federation
- May 4, 2022Phase 3 study in COVID-19NCT05364671 · 771 enrolled · Russia
- Feb 9, 20242 phase 3 studiesNCT06263881, NCT06284265
- Nov 29, 2024Phase 3 study in Acute Respiratory Viral InfectionNCT06715891 · 374 planned · Russia
- Mar 24, 2025Phase 3 study in RhinosinusitisNCT06901297 · 552 planned · Russia
- Jun 10, 2026Phase 3 study in BronchitisNCT07650227 · 308 planned · Russia
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Cystitis ChronicNCT06284265
- Dec 31, 2027Primary completion: phase 3 study in RhinosinusitisNCT06901297
- Dec 31, 2027Primary completion: phase 3 study in Acute Respiratory Viral InfectionNCT06715891
- Dec 31, 2028Primary completion: phase 3 study in BronchitisNCT07650227
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07650227Bronchitis · Russia | 3 | Recruiting | Dec 31, 2028 | 308 |
| NCT06901297Rhinosinusitis · Russia | 3 | Recruiting | Dec 31, 2027 | 552 |
| NCT06715891Acute Respiratory Viral Infection · Russia | 3 | Recruiting | Dec 31, 2027 | 374 |
| NCT06284265Cystitis Chronic · Russia | 3 | Active, not recruiting | Dec 31, 2026 | 415 |
| NCT06263881Community-Acquired Pneumonia · Russian Federation | 3 | Completed | Mar 19, 2025 | 370 |
| NCT05364671COVID-19 · Russia | 3 | Completed | Aug 18, 2023 | 771 |
| NCT04918771Acute Respiratory Viral Infection · Russian Federation | 3 | Completed | Jul 21, 2023 | 435 |
| NCT04250311Influenza, Human · Russian Federation | 3 | Suspended | Dec 2024 | 314 |
| NCT04244084Viral Respiratory Infection · Russian Federation | 3 | Completed | Apr 9, 2020 | 240 |
How it is read
Names in the registry
- “Raphamin”, 7 entries
- “MMH-407”, 2 entries
Codes read as this program: MMH407.
Conditions, from the studies’ own filings
- Bronchitis, 1 study
- Rhinosinusitis, 1 study
- Cystitis, 1 study
- Community-Acquired Pneumonia, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.